11. Share-Based Payments

The Company accounts for share-based compensation under the provisions of ASC 718, Compensation – Stock Compensation ("ASC 718"), which requires the Company to measure and recognize compensation expense for all share-based payments at fair value. Total share-based compensation expense included in the Consolidated Statements of Operations for Fiscal 2025, Fiscal 2024, and Fiscal 2023 was $39.4 million ($29.3 million, net of tax), $39.6 million ($29.5 million, net of tax), and $51.1 million ($36.2 million, net of tax), respectively.

 

There was $14.4 million of share-based payment expense, consisting of both time- and performance-based awards, included in gross profit for Fiscal 2025. This is compared to $14.2 million of share-based payment expense included in gross profit for Fiscal 2024.

 

There was $25.0 million of share-based payment expense, consisting of time and performance-based awards, included in selling, general, and administrative expenses this year. This is compared to $25.4 million of share-based payment expense included in selling, general, and administrative expenses for Fiscal 2024.

ASC 718 requires recognition of compensation cost under a non-substantive vesting period approach for awards containing provisions that accelerate or continue vesting upon retirement. Accordingly, for awards with such provisions, the Company recognizes compensation expense over the period from the grant date to the date that retirement eligibility is achieved, if that is expected to occur during the nominal vesting period. Additionally, for awards granted to retirement-eligible employees, the full compensation cost of an award must be recognized immediately upon grant.

At January 31, 2026, the Company had awards outstanding under two share-based compensation plans, which are described below.

Share-based compensation plans

2023 Stock Award and Incentive Plan ("2023 Plan")

The 2023 Plan was approved by the Company's stockholders on June 7, 2023. The 2023 Plan authorized 10.6 million shares for issuance, in the form of options, stock appreciation rights ("SARS"), restricted stock, restricted stock units, bonus stock and awards, performance awards, dividend equivalents and other stock-based awards. The 2023 Plan allows the Compensation Committee of the Board of Directors to determine which employees receive awards and the terms and conditions of the awards under the 2023 Plan. The 2023 Plan provides for grants to non-employee directors, which are not to exceed in value of $750,000 in any single fiscal year. As of January 31, 2026, approximately 4.8 million shares of restricted stock and approximately 2.1 million shares of common stock had been granted under the 2023 Plan to employees and non-employee directors. Approximately 30% of the restricted stock awards are performance-based and are earned if the pre-established performance goals are met. The remaining 70% of the restricted stock awards are time-based, of which 98% vest ratably over three years and 2% vest over a period of one to two years.

 

2020 Stock Award and Incentive Plan ("2020 Plan" and, together with the 2023 Plan, the "Plans")

 

The 2020 Plan was approved by the stockholders on April 13, 2020. The 2020 Plan authorized 10.2 million shares for issuance, in the form of options, SARS, restricted stock, restricted stock units, bonus stock and awards, performance awards, dividend equivalents and other stock-based awards. In connection with the adoption of the 2023 Plan, the 2020 Plan terminated on June 7, 2023 with all rights of the awardees and all unexpired awards continuing in force and operation after the termination. Through June 7, 2023, approximately 7.2 million shares of restricted stock and approximately 3.4 million shares of common stock had been granted under the 2020 Plan to employees and directors. Approximately 40% of the restricted stock awards are performance-based and are earned if the established performance goals are met. The remaining 60% of the restricted stock awards are time-based, of which 97% vest ratably over three years and 3% vest over a period of one to two years.

Stock Option Grants

The Company has granted time-based stock options under the Plans. Time-based stock option awards vest over the requisite service period of the award or to an employee’s eligible retirement date, if earlier.

A summary of the Company’s stock option activity for Fiscal 2025 follows:

 

 

 

Fiscal Year Ending January 31, 2026

 

 

 

 

 

 

Weighted-
Average

 

 

Weighted-
Average
Remaining
Contractual

 

 

Aggregate
Intrinsic

 

 

 

Options

 

 

Exercise Price

 

 

Term

 

 

Value

 

 

 

(In thousands)

 

 

 

 

 

(In years)

 

 

(In thousands)

 

Outstanding - February 1, 2025

 

 

4,324

 

 

$

17.98

 

 

 

 

 

 

 

Granted

 

 

1,343

 

 

 

12.59

 

 

 

 

 

 

 

Exercised (1)

 

 

(598

)

 

 

15.55

 

 

 

 

 

 

 

Cancelled

 

 

(526

)

 

 

21.14

 

 

 

 

 

 

 

Outstanding - January 31, 2026

 

 

4,543

 

 

$

16.34

 

 

 

3.8

 

 

$

35,658

 

Vested and expected to vest - January 31, 2026

 

 

4,384

 

 

$

16.28

 

 

 

3.6

 

 

$

35,503

 

Exercisable - January 31, 2026 (2)

 

 

2,066

 

 

$

14.50

 

 

 

2.5

 

 

$

18,213

 

 

(1)
Options exercised during Fiscal 2025 ranged in price from $8.62 to $24.37.
(2)
Options exercisable represent "in-the-money" vested options based upon the weighted average exercise price of vested options compared to the Company’s stock price on January 31, 2026.

The weighted-average grant date fair value of stock options granted during Fiscal 2025 and Fiscal 2024 was $4.12 and $10.61, respectively. The aggregate intrinsic value of options exercised during Fiscal 2025 and Fiscal 2024 was $4.4 million and $3.5 million, respectively. Cash received from the exercise of stock options and the actual tax detriment realized from share-based payments was $9.3 million and $1.5 million, respectively, for Fiscal 2025. Cash received from the exercise of stock options and the actual tax benefit realized from share-based payments was $3.8 million and $2.1 million, respectively, for Fiscal 2024.

As of January 31, 2026, there was $0.6 million of unrecognized compensation expense related to non-vested stock option awards that is expected to be recognized over a weighted average period of 1.9 years.

The fair value of stock options was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 

 

 

Fiscal Years Ending

 

 

January 31,

 

February 1,

Black-Scholes Option Valuation Assumptions

 

2026

 

2025

Risk-free interest rate (1)

 

3.9%

 

4.4%

Dividend yield

 

3.5%

 

1.9%

Volatility factor (2)

 

47.5%

 

55.4%

Weighted-average expected term (3)

 

4.5 years

 

4.5 years

 

 

(1)
Based on the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected life of our stock options.
(2)
Based on the historical volatility of the Company’s common stock.
(3)
Represents the period that options are expected to be outstanding. The weighted average expected option terms were determined based on historical experience.

Restricted Stock Grants

Time-based restricted stock awards are composed of time-based restricted stock units. These awards vest over one to three years. Time-based restricted stock units receive dividend equivalents in the form of additional time-based restricted stock units, which are subject to the same restrictions and forfeiture provisions as the original awards.

Performance-based restricted stock awards include performance-based restricted stock units. These awards cliff vest at the end of a three-year period based upon the Company’s achievement of pre-established goals throughout the term of the award. Performance-based restricted stock units receive dividend equivalents in the form of additional performance-based restricted stock units, which are subject to the same restrictions and forfeiture provisions as the original awards.

The grant date fair value of time-based restricted stock awards is based on the closing market price of the Company’s common stock on the date of grant. A Monte Carlo simulation was utilized for performance-based restricted stock awards.

A summary of the activity of the Company’s restricted stock is presented in the following tables:

 

 

 

Time-Based Restricted Stock Units

 

 

Performance-
Based Restricted Stock Units

 

 

 

Fiscal Year Ending

 

 

Fiscal Year Ending

 

 

 

January 31, 2026

 

 

January 31, 2026

 

(Shares in thousands)

 

Shares

 

 

Weighted-Average
Grant Date
Fair Value

 

 

Shares

 

 

Weighted-Average
Grant Date
Fair Value

 

Non-vested - February 1, 2025

 

 

2,360

 

 

$

18.56

 

 

 

2,218

 

 

$

18.05

 

Granted

 

 

2,109

 

 

 

12.68

 

 

 

1,096

 

 

 

14.53

 

Vested

 

 

(1,200

)

 

 

17.38

 

 

 

(563

)

 

 

19.69

 

Cancelled

 

 

(275

)

 

 

16.04

 

 

 

(307

)

 

 

18.61

 

Non-vested - January 31, 2026

 

 

2,994

 

 

$

15.12

 

 

 

2,444

 

 

$

16.02

 

 

 

As of January 31, 2026, there was $25.6 million of unrecognized compensation expense related to non-vested time-based restricted stock unit awards that is expected to be recognized over a weighted average period of 1.8 years. There was $5.0 million of unrecognized compensation expense related to performance-based restricted stock unit awards that is expected to be recognized over a weighted average period of 1.7 years.

As of January 31, 2026, the Company had 7.3 million shares available for all equity grants.

 

During Fiscal 2025 and Fiscal 2024, the Company repurchased approximately 0.7 million and 0.6 million shares, respectively, from certain employees at market prices totaling $7.9 million and $13.8 million, respectively. These shares were repurchased for the payment of taxes in connection with the vesting of share-based payments, as permitted under our equity incentive plans.

 

The aforementioned share repurchases have been recorded as treasury stock.

Historical Timeline

Fiscal YearFiled
2026Mar 30, 2026Showing above
2025Mar 20, 2025
2024Mar 15, 2024
2023Mar 13, 2023
2022Mar 14, 2022
2021Mar 11, 2021
2020Mar 12, 2020
2019Mar 14, 2019
2018Mar 16, 2018
2017Mar 10, 2017
2016Mar 10, 2016

About Stock Compensation Disclosures

Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.

Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.